EyePoint, Inc. EYPT
Set alert
At close
Pre-market · Nov 2, 9:20 AM ET
- YTD
- -98.09%
- 1 year
- -97.34%
- Open
- 0.37
- Prev close
- 0.3484
- Mkt cap
- 30.04M
- Vol
- 6.12M
- Avg vol
- 9.04M
- EPS
- -3.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3446
- High
- 0.3762
- Forward P/E
- -4.89
- Beta
- 1.74
- Short ratio
- 11.44
- Inst. own
- 111.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 13.11
- 200-d avg
- 14.14
- 1y target
- 40.93
5D chart
Signals (141)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:35 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:10 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:00 PM | 2 days ago |
| RSI: Oversold | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:10 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:55 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:35 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:10 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:50 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:20 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:15 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:15 AM | 6 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 6 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 6 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 6 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:05 PM | 6 days ago |
| RSI: Oversold | Oct 26, 3:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:40 PM | 6 days ago |
| RSI: Oversold | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:50 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:55 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:35 AM | 6 days ago |
News
4 days ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to…
4 days ago zacks.com
EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?
EyePoint (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 days ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to…
6 days ago globenewswire.com
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
EyePoint Pharmaceuticals shareholders lost nearly 67% of their share value in a single session after the Phase 3 LUCIA topline readout. Levi & Korsinsky is investigating potential securities law…
1 week ago globenewswire.com
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT)
DURAVYU's Phase 3 LUCIA trial missed its primary endpoint and EYPT shares lost nearly 80% of their value in a single session. Levi & Korsinsky is investigating on behalf of shareholders who may have…
1 week ago defenseworld.net
EyePoint (NASDAQ: EYPT) cuts 53% of staff after DURAVYU wet AMD miss
What happened EyePoint, Inc. (NASDAQ: EYPT) said on October 19, 2026 that it is shifting its focus to DURAVYU for diabetic macular edema after LUCIA missed its primary endpoint. The board approved a…
1 week ago gurufocus.com
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint PharmaceuticalsPR NewswireNEW YORK, Oct. 20, 2026
1 week ago prnewswire.com
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
EyePoint described its Phase 3 wet AMD trials as designed in close alignment with the FDA. LUCIA then missed its primary endpoint, and LUGANO's favorable result depended on excluding nine DURAVYU…
-
1 week ago benzinga.com
RBC Capital Maintains Sector Perform on EyePoint, Lowers Price Target to $1
RBC Capital analyst Lisa Walter maintains EyePoint (NASDAQ:EYPT) with a Sector Perform and lowers the price target from $5 to $1.
1 week ago benzinga.com
Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.
1 week ago prnewswire.com
EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)
EyePoint Pharmaceuticals shares lost nearly 80% of their value following the disappointing Phase 3 LUCIA trial results for DURAVYU in wet age-related macular degeneration. Levi & Korsinsky is…
1 week ago benzinga.com
Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 300 points on Monday.The Dow traded up 0.06% to 52,031.59 while the NASDAQ jumped 1.24% to 26,465.39.…
1 week ago benzinga.com
EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus
EyePoint Inc. (NASDAQ:EYPT) is slashing its workforce by 53% and halting wet age-related macular degeneration clinical trials early following disappointing Phase 3 results.
1 week ago benzinga.com
EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus
EyePoint cuts 53% of staff and halts wet AMD trials after DURAVYU misses its Phase 3 primary endpoint, pivoting its focus entirely to DME.
1 week ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX)…
1 week ago seekingalpha.com
EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration Prepared Remarks Transcript
EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration Prepared Remarks Transcript
2 weeks ago benzinga.com
Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views
U.S. stocks mixed: Nasdaq +1.09%, S&P 500 +0.54%, Dow -0.12%. Tech led gains; utilities lagged. Oil fell, gold rose; Europe lower.
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved…
2 weeks ago globenewswire.com
EyePoint Announces Strategic Prioritization
WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with…
-
2 weeks ago benzinga.com
Eyepoint Says Topline Results From Lucia Phase 3 Trial Of Duravyu (Vorolanib Intravitreal Insert) For Wet Age-Related Macular Degeneration Did Not Achieve The Primary Endpoint
– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement –– Key secondary…
2 weeks ago globenewswire.com
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD
– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement – – Key secondary…
2 weeks ago defenseworld.net
Comparing Eyepoint Pharmaceuticals (NASDAQ:EYPT) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Eyepoint Pharmaceuticals (NASDAQ: EYPT - Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ: SXTP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We…
2 weeks ago zacks.com
Here's Why You Should Add EYPT Stock to Your Portfolio Now
EyePoint's Duravyu faces a key LUCIA study data readout in late 2026, with results potentially paving the way for an NDA filing in 2027.
3 weeks ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to…
4 weeks ago defenseworld.net
Contrasting Eyepoint Pharmaceuticals (NASDAQ:EYPT) & GSK (NYSE:GSK)
GSK (NYSE: GSK - Get Free Report) and Eyepoint Pharmaceuticals (NASDAQ: EYPT - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies…
1 month ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to…
1 month ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to…
1 month ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT).
1 month ago benzinga.com
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsychiatric adverse events; other stocks also fall
2 months ago benzinga.com
This Toast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday
Wall Street analysts changed outlook on top companies. Check out complete rating changes, including upgrades/downgrades, on our page.
-
2 months ago benzinga.com
TD Cowen Downgrades EyePoint to Hold, Lowers Price Target to $4
TD Cowen analyst Tara Bancroft downgrades EyePoint (NASDAQ:EYPT) from Buy to Hold and lowers the price target from $20 to $4.
2 months ago benzinga.com
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
2 months ago benzinga.com
These Analysts Slash Their Forecasts On EyePoint
EYPT releases topline results from Phase 3 LUGANO trial for wet AMD treatment. While primary endpoint was not met, secondary endpoints showed progress. Analysts adjust price targets.
-
2 months ago benzinga.com
Citigroup Maintains Buy on EyePoint, Lowers Price Target to $17
Citigroup analyst Yigal Nochomovitz maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $35 to $17.
-
2 months ago benzinga.com
RBC Capital Downgrades EyePoint to Sector Perform, Lowers Price Target to $5
RBC Capital analyst Lisa Walter downgrades EyePoint (NASDAQ:EYPT) from Outperform to Sector Perform and lowers the price target from $37 to $5.
-
2 months ago benzinga.com
Chardan Capital Downgrades EyePoint to Neutral, Lowers Price Target to $5
Chardan Capital analyst Andreas Argyrides downgrades EyePoint (NASDAQ:EYPT) from Buy to Neutral and lowers the price target from $65 to $5.
2 months ago benzinga.com
Nike, Meta Platforms, INVO Fertility, EyePoint Pharmaceuticals, and Micron: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices ended lower on Monday, with the Dow Jones Industrial Average falling 0.51% to 53,459.78
2 months ago benzinga.com
Why Is Ocular Therapeutix Stock Gaining Monday?
Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's regular session. The market value of their outstanding shares is at $1.7 million. As per the press release,…
-
2 months ago benzinga.com
Jefferies Maintains Buy on EyePoint, Lowers Price Target to $8
Jefferies analyst Kambiz Yazdi maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $30 to $8.
2 months ago benzinga.com
Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August
US stocks mixed, S&P 500 drops 0.2%. Dow down 0.34%, NASDAQ up 0.04%. Industrials up 0.2%, consumer staples down 1%. NY Fed's Empire State Index at 20.6.
2 months ago benzinga.com
EyePoint Stock Plummets on Mixed Primary Data From Blindness Drug Study
EyePoint reported Phase 3 LUGANO trial results for DURAVYU, highlighting reduced treatment burden despite primary endpoint challenges.
2 months ago benzinga.com
Dow Falls 150 Points; NY Empire State Manufacturing Index Rises In August
US stocks mixed, Dow falls 150 points. Dow down 0.31%, NASDAQ up 0.03%, S&P 500 down 0.12%. Tech shares up 0.4%, consumer staples down 0.8%.
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-market session. The company's market cap stands at $1.7 million. GlucoTrack (NASDAQ:GCTK) shares moved…
-
2 months ago benzinga.com
EyePoint Reports DURAVYU Non‑Inferior To Aflibercept In Ad Hoc Analysis; Primary BCVA Endpoint Not Met In Full Dataset
EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced topline…
-
2 months ago benzinga.com
EyePoint Announces Topline Results From LUGANO, First Pivotal Phase 3 Clinical Trial For DURAVYU For Treatment Of Wet Age-Related Macular Degeneration
– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15…
2 months ago benzinga.com
Paycom Software To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts changed outlook on top names: JP Morgan cut price target for Insulet, HC Wainwright slashed EyePoint's target, Goldman cut Sunrun's, B of A lowered Coupang's, BTIG cut Klaviyo's, Jefferies…
-
2 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on EyePoint, Raises Price Target to $55
Cantor Fitzgerald analyst Steve Seedhouse maintains EyePoint (NASDAQ:EYPT) with a Overweight and raises the price target from $47 to $55.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on EyePoint, Lowers Price Target to $27
HC Wainwright & Co. analyst Yi Chen maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $30 to $27.
-
2 months ago benzinga.com
EyePoint Pharmaceuticals Q2 EPS $(1.09) Misses $(0.95) Estimate, Sales $507.000K Beat $406.857K Estimate
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.95) by 14.74 percent. This is a 28.24 percent decrease over…